Listen to The Lancet Haematology

Dr Jose Leal discusses a study of the costs related to malignant and non-malignant blood disorders in Europe in 2012.

David Fajgenbaum discusses a literature review to raise awareness of idiopathic multicentric Castleman disease, a poorly understood haematological disorder.

Walter Ageno discusses the use of an algorithm combining limited and whole-leg compression ultrasonography to diagnose deep-vein thrombosis.

Scott Huntington discusses the financial toxicity of oncology treatments

James Bussel discusses a study looking at treatment options for children facing idiopathic thrombocytopenic purpura.

Klervi Leuraud discusses a study reporting on the risk of developing leukaemia and lymphoma in workers monitored for radiation exposure.

Páll Önundarson describes a new method for monitoring clotting in patients treated with warfarin, which they tested in a non-inferiority, randomised clinical trial.

Mahmoud Zureik discusses risk of bleeding in patients with non-valvular atrial fibrillation who switched and those who remained on a vitamin K antagonist.

Dietger Niederwieser and Richard Lane discuss the journey to 1 million haematopoietic stem cell transplantations.

Guillermo Garcia-Manero discusses a phase 1/2 study on sequential azacitidine and lenalidomide in high-risk MDS and AML.

Gregory Kato discusses a phase I study for the treatment of leg ulcers for people with sickle-cell disease.

Dr Odejide and Dr Kuczmarski tell us about a study recently published in  The Lancet Haematology  on the effect of pre-existing mental health conditions on survival in patients with diffuse large B-cell lymphoma.

Professor Johannes Schetelig joins us to discuss the results of the ASAP phase 3 trial comparing remission induction with immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia.

With a growing number of treatment options for blood cancers, understanding the side effects from these treatments and how they affect patients is becoming ever more important. Join a panel of authors from The Lancet Haematology's latest series on Adverse Event reporting to discuss how we can improve clinical trial design and analysis, and translate this data to meaningful, patient-centric ca...

The Lancet Haematology  share their thoughts and reflect on their experiences at the European Hematology Association, International Conference on Malignant Lymphoma, and International Society on Thrombosis and Haemostasis meetings.

Dr Erica Kaye and Dr Dylan Graetz join us to discuss the importance of qualitative research and how the whole research ecosystem can incorporate and support this type of research to help set the right research questions, and promote the patient voice.